U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C6H14N2.C2O4.Pt.2HO
Molecular Weight 431.306
Optical Activity UNSPECIFIED
Additional Stereochemistry Yes
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0
Stereo Comments SQUARE PLANAR, CIS-

SHOW SMILES / InChI
Structure of DIHYDROXY OXALIPLATIN-PT(IV)

SMILES

[OH-].[OH-].[Pt+4].[O-]C(=O)C([O-])=O.[H][C@@]1(N)CCCC[C@@]1([H])N

InChI

InChIKey=CRUOOYJLGQUXMM-NDSUJOINSA-J
InChI=1S/C6H14N2.C2H2O4.2H2O.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;;;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);2*1H2;/q;;;;+4/p-4/t5-,6-;;;;/m1..../s1

HIDE SMILES / InChI

Molecular Formula C2O4
Molecular Weight 88.019
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C6H14N2
Molecular Weight 114.1888
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Pt
Molecular Weight 195.084
Charge 4
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.medkoo.com/products/5702

Ormaplatin (NSC 363812, tetraplatin) is a stable platinum (IV) analog. Ormaplatin alkylates DNA, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. Ormaplatin showed marked antitumor activity both in vitro and vivo. The severe, cumulative and irreversible peripheral neurotoxicity observed in phase I studies resulted in termination of further clinical development of ormaplatin.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.78 mg/L
98 mg/m² single, intravenous
dose: 98 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PLATINUM (IV) ION plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.576 mg/L
78 mg/m² single, intravenous
dose: 78 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PLATINUM (IV) ION plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.995 mg/L
123 mg/m² single, intravenous
dose: 123 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PLATINUM (IV) ION plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.37 mg × h/L
98 mg/m² single, intravenous
dose: 98 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PLATINUM (IV) ION plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6.62 mg × h/L
78 mg/m² single, intravenous
dose: 78 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PLATINUM (IV) ION plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
8.05 mg × h/L
123 mg/m² single, intravenous
dose: 123 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PLATINUM (IV) ION plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.9 min
98 mg/m² single, intravenous
dose: 98 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PLATINUM (IV) ION plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
16.2 min
78 mg/m² single, intravenous
dose: 78 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PLATINUM (IV) ION plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
10.5 min
123 mg/m² single, intravenous
dose: 123 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PLATINUM (IV) ION plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
30%
98 mg/m² single, intravenous
dose: 98 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PLATINUM (IV) ION plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
30%
78 mg/m² single, intravenous
dose: 78 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PLATINUM (IV) ION plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
30%
123 mg/m² single, intravenous
dose: 123 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PLATINUM (IV) ION plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines.
1993 Apr
Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812).
1999

Sample Use Guides

A phase I trial of ormaplatin administered as a 1-h infusion every 4 weeks was performed. Forty-one patients received 101 cycles of drug over the dose range 4-128 mg/m2.
Route of Administration: Intravenous
In Vitro Use Guide
10 uM tetraplatin (ormaplatin) is cytotoxic for L1210 leukemia cells
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:16:46 GMT 2023
Edited
by admin
on Sat Dec 16 09:16:46 GMT 2023
Record UNII
AXA37HSS7Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIHYDROXY OXALIPLATIN-PT(IV)
Common Name English
(OC-6-33)-((1R,2R)-CYCLOHEXANE-1,2-DIAMINE.KAPPA.N,.KAPPA.N')(ETHANEDIOATO(2-)-.KAPPA.O1,.KAPPA.O2)DIHYDROXYPLATINUM
Systematic Name English
OXALIPLATIN RELATED COMPOUND C
Common Name English
OXALIPLATIN IMPURITY C [EP IMPURITY]
Common Name English
((1R-TRANS-(1,2-CYCLOHEXANEDIAMINE-N,N'))-TRANS-DIHYDROXIDO-(OXALATO(2-)-O,O')PLATINUM(IV))
Common Name English
OXALIPLATIN RELATED COMPOUND C [USP IMPURITY]
Common Name English
PLATINUM, ((1R,2R)-1,2-CYCLOHEXANEDIAMINE-.KAPPA.N1,.KAPPA.N2)(ETHANEDIOATO(2-)-.KAPPA.O1,.KAPPA.O2)DIHYDROXY-, (OC-6-33)-
Systematic Name English
Code System Code Type Description
CAS
111321-67-6
Created by admin on Sat Dec 16 09:16:46 GMT 2023 , Edited by admin on Sat Dec 16 09:16:46 GMT 2023
PRIMARY
EPA CompTox
DTXSID60747681
Created by admin on Sat Dec 16 09:16:46 GMT 2023 , Edited by admin on Sat Dec 16 09:16:46 GMT 2023
PRIMARY
FDA UNII
AXA37HSS7Z
Created by admin on Sat Dec 16 09:16:46 GMT 2023 , Edited by admin on Sat Dec 16 09:16:46 GMT 2023
PRIMARY
PUBCHEM
129011603
Created by admin on Sat Dec 16 09:16:46 GMT 2023 , Edited by admin on Sat Dec 16 09:16:46 GMT 2023
PRIMARY
RS_ITEM_NUM
1481237
Created by admin on Sat Dec 16 09:16:46 GMT 2023 , Edited by admin on Sat Dec 16 09:16:46 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP